A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety

A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells

(2022) Youg R. Thaker et al.   Frontiers in Oncology

A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC

(2021) Kaixin Du et al.   MOLECULAR THERAPY

Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study.

(2021) Hui Kong Gan et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer

(2021) Lei Tian et al.   CLINICAL CANCER RESEARCH

PKAD: a database of experimentally measured pKa values of ionizable groups in proteins

(2019) Swagata Pahari et al.   Database-The Journal of Biological Databases and Curation

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

(2019) Branimir I. Sikic et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Inhibition of CD47-SIRPα Requires Fc-FcγR Interactions to Maximize Activity in T-cell Lymphomas

(2019) Salvia Jain et al.   BLOOD

TJC4, a Differentiated Anti-CD47 Antibody with Novel Epitope and RBC Sparing Properties

(2019) Zhen Meng et al.   BLOOD

Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab

(2019) Judith Petersen et al.   BLOOD

Structure-based engineering of pH-dependent antibody binding for selective targeting of solid-tumor microenvironment

(2019) Traian Sulea et al.   mAbs

Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action

(2018) Douglas Sheridan et al.   PLoS One

ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile

(2018) Steven E. Kauder et al.   PLoS One

Systems analysis of intracellular pH vulnerabilities for cancer therapy

(2018) Erez Persi et al.   Nature Communications

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors

(2017) Sharareh Gholamin et al.   Science Translational Medicine

Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies

(2017) E C Pietsch et al.   Blood Cancer Journal

Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2017) Stephen K Horrigan et al.   eLife

A potent human neutralizing antibody Fc-dependently reduces established HBV infections

(2017) Dan Li et al.   eLife

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

(2016) Penka S. Petrova et al.   CLINICAL CANCER RESEARCH

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

(2016) Kipp Weiskopf et al.   JOURNAL OF CLINICAL INVESTIGATION

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

(2016) Jonathan T. Sockolosky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma

(2015) Zhenyu Xiao et al.   CANCER LETTERS

 De novoisolation of antibodies with pH-dependent binding properties

(2015) Pauline Bonvin et al.   mAbs

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities

(2015) Falk Nimmerjahn et al.   TRENDS IN IMMUNOLOGY

T-cell exhaustion in the tumor microenvironment

(2015) Y Jiang et al.   Cell Death & Disease

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

(2015) Jie Liu et al.   PLoS One

The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target

(2013) A. Neil Barclay et al.   Annual Review of Immunology

Acidity Generated by the Tumor Microenvironment Drives Local Invasion

(2013) V. Estrella et al.   CANCER RESEARCH

Engineered SIRP  Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies

(2013) K. Weiskopf et al.   SCIENCE

Properties of mouse and human IgG receptors and their contribution to disease models

(2012) P. Bruhns   BLOOD

Increasing Serum Half-life and Extending Cholesterol Loweringin Vivoby Engineering Antibody with pH-sensitive Binding to PCSK9

(2012) Javier Chaparro-Riggers et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Crosstalk between Human IgG Isotypes and Murine Effector Cells

(2012) M. B. Overdijk et al.   JOURNAL OF IMMUNOLOGY

Inhibitory signaling through signal regulatory protein-  is not sufficient to explain the antitumor activities of CD47 antibodies

(2012) D. R. Soto-Pantoja et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Integration, scaling, space-group assignment and post-refinement

(2010) Wolfgang Kabsch   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Features and development ofCoot

(2010) P. Emsley et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

PHENIX: a comprehensive Python-based system for macromolecular structure solution

(2010) Paul D. Adams et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization

(2010) Tomoyuki Igawa et al.   NATURE BIOTECHNOLOGY

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE

Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD47

(2008) Deborah Hatherley et al.   MOLECULAR CELL

Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate

(2008) Ferdia A. Gallagher et al.   NATURE